Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333255 · ClinicalTrials.gov registry record · Phase 3
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 267
- Enrollment target
NCT00333255 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 267 participants.
The verdict
NCT00333255, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 267 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
Interventions
- DRUG Nepafenac Ophthalmic Suspension, 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333255
The ClinicalTrials.gov registry entry for NCT00333255 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nepafenac Ophthalmic Suspension, 0.1% is the first listed.
NCT00333255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333255 about?
NCT00333255 is a clinical study titled "Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery". The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
What is the current status of trial NCT00333255?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 267 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00333255?
The interventions under investigation include: Nepafenac Ophthalmic Suspension, 0.1% (DRUG).
Who is sponsoring clinical trial NCT00333255?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.